Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...

(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...

Moderna said on Wednesday it would stop developing its experimental vaccine to prevent cytomegalovirus, a virus that can ...

While development has been scrapped in CMV, a Phase II trial investigating the candidate in bone marrow transplant patients ...

It's a significant setback for the Cambridge company, which is already facing pressure from Wall Street and the federal ...

Moderna is halting development of an mRNA vaccine for congenital cytomegalovirus after its candidate failed to protect women ...

Moderna’s oncology pipeline also includes a Merck-partnered personalized cancer vaccine called intismeran autogene or ...

Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...

Moderna halts late-stage CMV vaccine trial after unmet goals but maintains 2025 financial outlook. Read more here.

A key question for investors going forward will be whether Moderna's other latent virus vaccines for Epstein-Barr and shingles can succeed after the failure of the CMV program.

The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from just 6% to 23% depending on the case definition used. As a result, Moderna ...

But this research team found its results so promising that it is preparing a more rigorous study to see if mRNA coronavirus ...